| Literature DB >> 15256058 |
Paola Secchiero1, Arianna Gonelli, Edvige Carnevale, Federica Corallini, Clara Rizzardi, Serena Zacchigna, Mauro Melato, Giorgio Zauli.
Abstract
Starting from the observation that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo-2L protein is expressed in both malignant and inflammatory cells in some highly vascularized soft tissue sarcomas, the angiogenic potential of TRAIL was investigated in a series of in vitro assays. Recombinant soluble TRAIL induced endothelial cell migration and vessel tube formation to a degree comparable to vascular endothelial growth factor (VEGF), one of the best-characterized angiogenic factors. However, the proangiogenic activity of TRAIL was not mediated by endogenous expression of VEGF. Although TRAIL potentiated VEGF-induced extracellular signal-regulated kinase (ERK) phosphorylation and endothelial cell proliferation, the combination of TRAIL + VEGF did not show additive effects with respect to VEGF alone in inducing vessel tube formation. Thus, although TRAIL has gained attention as a potential anticancer therapeutic for its ability to induce apoptosis in a variety of cancer cells, our present data suggest that TRAIL might also play an unexpected role in promoting angiogenesis, which might have therapeutic implications. Copyright 2004 Neoplasia Press, Inc.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15256058 PMCID: PMC1502116 DOI: 10.1593/neo.03421
Source DB: PubMed Journal: Neoplasia ISSN: 1476-5586 Impact factor: 5.715